Nexgel, Inc. NXGL
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
Nexgel, Inc. (NXGL) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $12M and net income of -$6M, a net margin of -51.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 76% a year, a 5-year average ROIC of -31%.
About Nexgel
Nexgel is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $2M in 2018 to $11M in 2025, growth of about 26.4% a year. It was profitable in 0 of the last 8 years in our data. Its share count rose by 41% over three years (dilution for shareholders). It spends 0% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $11M | $9M | $4M | $2M | $2M | $674000 | $717000 | $2M |
| Net income | -$6M | -$3M | -$3M | -$3M | -$5M | -$4M | -$2M | -$2M | -$2M |
| Free cash flow | -$10M | -$1M | -$4M | -$4M | -$3M | -$3M | -$2M | -$2M | — |
| EPS (diluted) | $-10.65 | $-5.70 | $-7.50 | $-8.40 | $-12.75 | $-21.75 | $-15.75 | $-73.50 | $-199.50 |
| Net margin | -51.3% | -26.3% | -37.8% | -77.2% | -231.7% | -277.9% | -335.9% | -268.2% | -85.3% |
| ROIC | — | -36.6% | -34.2% | -37.0% | -34.4% | -12.4% | -85.8% | -117.2% | -114.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Nexgel pay a dividend?
Not currently.
Is Nexgel a good stock to buy?
We do not give buy or sell advice. Nexgel scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.